- Home
- ZIMV vs OABI Comparison
ZIMV vs OABI Comparison
Compare ZIMV & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- OABI
- Stock Information
- Founded
- ZIMV 2021
- OABI 2012
- Country
- ZIMV United States
- OABI United States
- Employees
- ZIMV N/A
- OABI N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- ZIMV Health Care
- OABI Health Care
- Exchange
- ZIMV Nasdaq
- OABI Nasdaq
- Market Cap
- ZIMV 262.9M
- OABI 250.8M
- IPO Year
- ZIMV N/A
- OABI N/A
- Fundamental
- Price
- ZIMV $18.78
- OABI $2.15
- Analyst Decision
- ZIMV Hold
- OABI Strong Buy
- Analyst Count
- ZIMV 3
- OABI 3
- Target Price
- ZIMV $14.50
- OABI $7.00
- AVG Volume (30 Days)
- ZIMV 779.6K
- OABI 615.6K
- Earning Date
- ZIMV 08-04-2025
- OABI 08-06-2025
- Dividend Yield
- ZIMV N/A
- OABI N/A
- EPS Growth
- ZIMV N/A
- OABI N/A
- EPS
- ZIMV N/A
- OABI N/A
- Revenue
- ZIMV $443,551,000.00
- OABI $26,744,000.00
- Revenue This Year
- ZIMV $1.96
- OABI N/A
- Revenue Next Year
- ZIMV $1.95
- OABI $45.02
- P/E Ratio
- ZIMV N/A
- OABI N/A
- Revenue Growth
- ZIMV N/A
- OABI 27.07
- 52 Week Low
- ZIMV $8.15
- OABI $1.22
- 52 Week High
- ZIMV $22.18
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- ZIMV 87.34
- OABI 66.40
- Support Level
- ZIMV $8.36
- OABI $1.90
- Resistance Level
- ZIMV $18.98
- OABI $2.11
- Average True Range (ATR)
- ZIMV 0.34
- OABI 0.15
- MACD
- ZIMV 1.10
- OABI 0.00
- Stochastic Oscillator
- ZIMV 98.12
- OABI 71.29
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.